EcoR1 Capital, LLC bought $18M of ZYME
director, owner at Zymeworks Inc.. 1,254,808 shares at an average of $13.98, traded Dec 19, 2024, filed Dec 26, 2024.
Score components
- +15RoleDirector
- +25Trade size$17.5M at market
- +3Relative to holdingsHoldings up 9%
- +4Price context22% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000935836-24-000780, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2024 | POpen-market purchase Common Stockindirect: See Note | +298,818 | $13.53 | $4.0M | 13,736,291 | Dec 26, 2024 |
| Dec 20, 2024 | POpen-market purchase Common Stockindirect: See Note | +704,488 | $14.08 | $9.9M | 14,440,779 | Dec 26, 2024 |
| Dec 23, 2024 | POpen-market purchase Common Stockindirect: See Note | +251,502 | $14.25 | $3.6M | 14,692,281 | Dec 26, 2024 |
Related signals
Other insiders at Zymeworks Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | ZYMEsell Zymeworks Inc. | Adam Schayowitz EVP, Head of R&D | $358k 13,832 shares | -37% | |
| 31Weak | Zymeworks Inc. | Mark Hollywood EVP & Chief Operating Officer | $139k 6,120 shares | -4% | |
| 51Moderate | Zymeworks Inc. | Kenneth Galbraith Chair & CEO | $690k 30,424 shares | -12% | |
| 32Weak | Zymeworks Inc. | Paul Andrew Moore Chief Scientific Officer | $217k 9,560 shares | -16% | |
| 37Weak | Zymeworks Inc. | Jeffrey T L Smith EVP & Chief Medical Officer | $211k 9,310 shares | -26% | |
| 60Notable | Zymeworks Inc. | Kenneth Galbraith Chair & CEO | $1.4M 54,343 shares | -30% | |
| 43Moderate | Zymeworks Inc. | Paul Andrew Moore Chief Scientific Officer | $505k 20,110 shares | -50% | |
| 38Weak | Zymeworks Inc. | Jeffrey T L Smith EVP & Chief Medical Officer | $264k 10,538 shares | -36% | |
| 60Notable | Zymeworks Inc. | Kenneth Galbraith Chair & CEO | $1.3M 47,528 shares | -26% | |
| 43Moderate | ZYMEbuy Zymeworks Inc. | EcoR1 Capital, LLC director, owner | $636k 55,421 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.